Improving antithrombotic treatment in patients after myocardial infarction.
D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D000077144:Clopidogrel; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005998:Glycine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D016896:Treatment Outcome; D014859:Warfarin / Q000627:therapeutic use
D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; C109573:melagatran; C426686:ximelagatran; D014859:Warfarin; D000077144:Clopidogrel; D013988:Ticlopidine; D005998:Glycine